U.S. FDA declines to approve Merck's cough treatment
Reuters
Published Jan 24, 2022 07:00AM ET
Updated Jan 24, 2022 07:21AM ET
(Reuters) -Merck & Co said on Monday the U.S. Food and Drug Administration declined to approve its experimental drug for the treatment of chronic cough and sought additional information on the treatment's effectiveness.
Merck said it would meet with the agency to discuss the next steps on the oral drug, gefapixant.
Shares in the company were down about 0.5% at $79.6 before the bell.
If approved later, gefapixant would become the first such remedy for patients who have a persisting cough after the treatment of underlying health conditions such as asthma or if they have an unexplained chronic cough, Merck said.
Last week, Japan's health regulator approved gefapixant tablets for adults with refractory or unexplained chronic cough, to be marketed under the brand name Lyfnua.
The FDA's decision was not related to the drug's safety, Merck said.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.